Abstract Background and Purpose Non-muscle-invasive bladder cancer (NMIBC) constitutes
a heterogeneous group of tumors with different prognoses. This population-based study …

Abstract Poor response to Bacillus Calmette-Guérin (BCG) immunotherapy remains a major
barrier in the management of patients with non–muscle invasive bladder cancer (NMIBC) …

Abstract Background Ta grade 3 (G3) non–muscle-invasive bladder cancer (NMIBC) is a
relatively rare diagnosis with an ambiguous character owing to the presence of an …

Simple Summary Bladder cancer remains the most common malignancy of urinary tract. Sex-
related divergent outcomes in bladder cancer have been reported with controversial results …

Sex-specific discrepancies in bladder cancer (BCa) are reported, and new studies imply that
microbiome may partially explain the diversity. We aim to provide characterization of the …

Abstract Intravesical bacillus Calmette-Guérin (BCG) G immunotherapy is the gold standard
treatment for patients with non-muscle invasive bladder cancer (NMIBC). Unfortunately …

Objective This study aims to investigate the impact of risk group classification, restaging
transurethral resection (re‐TURBT), and adjuvant treatment intensity on recurrence and …

A patient's visit for a new diagnosis of nonmuscle invasive bladder cancer (NMIBC)
represents the start of a lifelong, sometimes winding journey of bladder cancer surveillance …

In this issue of The Journal of Urology®, loyal readers will find 3 intriguing articles from our
New Technology and Techniques section, expertly led by Feature Editor Dr Inderbir S. Gill …

Treatment-naïve tumors from patients who then experience recurrence or progression after
bacillus Calmette-Guérin (BCG) therapy exhibit elevated expression of genes associated …